Pay-For-Delay Deals Hit 7-Year High In 2010: FTC

Law360, New York (May 3, 2011, 8:01 PM EDT) -- The number of so-called pay-for-delay deals between name-brand pharmaceutical companies and their generics competitors jumped by 60 percent in 2010, covering nearly two dozen drugs with $9.3 billion in U.S. sales, the Federal Trade Commission said Tuesday.

A new staff report from the U.S. competition watchdog turned up 31 deals in which pharmaceutical companies that make brand-name drugs paid generic manufacturers to keep cheaper alternatives off the market from October 2009 through September 2010.

Up from 19 in the previous fiscal year, the 2010 figure is...
To view the full article, register now.